Evidence map›Paper›PMID 41939467›Full record

ArticleFrontiers in oncology2026

Recent trends in lipid metabolism research in liver cancer: a bibliometric analysis.

Yaru Shi, Xinyu Yang, Yunfeng Yu, Yanan Bai, Pei Liu, Jianzhong Cao, Weibin Xie

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yaru Shi *Department of Integrated Traditional Chinese and Western Medicine, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Xinyu Yang *School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.
Yunfeng YuSchool of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.
Yanan BaiSchool of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.
Pei LiuSchool of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.
Jianzhong CaoSchool of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.
Weibin XieDepartment of Integrated Traditional Chinese and Western Medicine, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This study aims to systematically map the intellectual landscape and emerging trends in lipid metabolism research within hepatocellular carcinoma from 2014 to 2024. Methods: A total of 607 peer-reviewed publications were retrieved from the Web of Science Core Collection and PubMed. Bibliometric and visualization tools, including VOSviewer and CiteSpace, were employed to perform data analysis, including keyword co-occurrence and cluster analysis. Results: We identified a significant surge in research activity, with 53.05% of the total literature published in the last three years. China and the USA emerged as the leading contributors, with the University of California System and the journal Cancers being the most prolific institution and publication outlet, respectively. Current research hotspots are centered on the mechanisms by which oxidative stress drives the transformation of non-alcoholic fatty liver disease into hepatocellular carcinoma. Furthermore, three critical frontiers for future investigation were identified: (1) the regulatory role of PPARγ in lipid metabolic reprogramming and its therapeutic implications; (2) the molecular mechanisms of the farnesoid X receptor in modulating bile acid metabolism during hepatocarcinogenesis; and (3) the NF-κB signaling pathways that mediate metabolic shifts and confer chemoresistance in liver cancer. Discussion: These findings provide a comprehensive reference for prioritizing research directions and therapeutic target discovery in the metabolic-related oncology domain.

Indexed as

bibliometricsCitespacelipid metabolismliver cancerVOSviewer

Identifiers

PMID41939467
PMCPMC13043338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.